different ways of analys<strong>in</strong>g and present<strong>in</strong>g results. Pa<strong>in</strong>2005;116(3):322–31. [DOI: 10.1016/j.<strong>pa<strong>in</strong></strong>.2005.05.001]Morris 1995Morris JA, Gardner MJ. Calculat<strong>in</strong>g confidence <strong>in</strong>tervals<strong>for</strong> relative risk, odds ratio and standardised ratios and rates.In: Gardner MJ, Altman DG editor(s). Statistics withconfidence - confidence <strong>in</strong>tervals and statistical guidel<strong>in</strong>es.London: British Medical Journal, 1995:50–63.Oldman 2000Oldman A, Smith LA, Coll<strong>in</strong>s S, Carroll D, Wiffen PJ,McQuay HJ, et al.<strong>S<strong>in</strong>gle</strong> <strong>dose</strong> <strong>oral</strong> aspir<strong>in</strong> <strong>for</strong> <strong>acute</strong> <strong>pa<strong>in</strong></strong>.Cochrane Database of Systematic Reviews 2000, Issue 2.[DOI: 10.1002/14651858.CD002067]PACT 2007Prescription Cost Analysis . England 2007. [ISBN:978–1–84636–210–1]Rapoport 1999Rapoport RJ. The Safety of NSAIDs and Related Drugs<strong>for</strong> the Management of Acute Pa<strong>in</strong>: Maximiz<strong>in</strong>g Benefitsand M<strong>in</strong>imiz<strong>in</strong>g Risks. Cancer Control 1999;6(2 Suppl 1):18–21.Roy 2007Roy YM, Derry S, Moore RA. <strong>S<strong>in</strong>gle</strong> <strong>dose</strong> <strong>oral</strong>lumiracoxib <strong>for</strong> <strong>postoperative</strong> <strong>pa<strong>in</strong></strong>. Cochrane Databaseof Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006865]Toms 2008Toms L, McQuay HJ, Derry S, Moore RA. <strong>S<strong>in</strong>gle</strong> <strong>dose</strong> <strong>oral</strong>paracetamol (acetam<strong>in</strong>ophen) <strong>for</strong> <strong>postoperative</strong> <strong>pa<strong>in</strong></strong> <strong>in</strong><strong>adults</strong>. Cochrane Database of Systematic Reviews 2008, Issue4. [DOI: 10.1002/14651858.CD004602]Tramèr 1997Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ.Impact of covert duplicate results on meta-analysis: a casestudy. BMJ 1997;315:635–9.References to other published versions of this reviewBarden 2004aBarden J, Edwards J, Moore RA, McQuay HJ. <strong>S<strong>in</strong>gle</strong> <strong>dose</strong><strong>oral</strong> <strong>diclofenac</strong> <strong>for</strong> <strong>postoperative</strong> <strong>pa<strong>in</strong></strong>. Cochrane Databaseof Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004768]Coll<strong>in</strong>s 1998Coll<strong>in</strong>s SL, Moore RA, McQuay HJ, Wiffen PJ. Oralibuprofen and <strong>diclofenac</strong> <strong>in</strong> <strong>postoperative</strong> <strong>pa<strong>in</strong></strong>: aquantitative systematic review. European Journal of Pa<strong>in</strong>1998;2(4):285–91.∗ Indicates the major publication <strong>for</strong> the study<strong>S<strong>in</strong>gle</strong> <strong>dose</strong> <strong>oral</strong> <strong>diclofenac</strong> <strong>for</strong> <strong>acute</strong> <strong>postoperative</strong> <strong>pa<strong>in</strong></strong> <strong>in</strong> <strong>adults</strong> (Review)Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.24
C H A R A C T E R I S T I C S O F S T U D I E SCharacteristics of <strong>in</strong>cluded studies [ordered by study ID]Ahlstrom 1993MethodsParticipantsRCT, DB, double dummy, s<strong>in</strong>gle <strong>oral</strong> <strong>dose</strong>, 3 parallel groupsMedication adm<strong>in</strong>istered when basel<strong>in</strong>e <strong>pa<strong>in</strong></strong> was of moderate to severe <strong>in</strong>tensityPa<strong>in</strong> assessed at 0, 20, 40, 60 m<strong>in</strong>s then hourly up to 6 hoursThird molar extractionN = 97M = 46, F = 51Mean age 25 yrsInterventions Diclofenac (soluble) 50 mg, n = 35Ibuprofen (tablets) 400 mg, n = 32Placebo, n = 30OutcomesNotesPI: std 100 mm VASPR: std 100 mm VASPGE: std 5 po<strong>in</strong>t scaleOx<strong>for</strong>d Quality Score: R1, DB2, W1No details about rescue medication used or any restrictions on time be<strong>for</strong>e use was permittedBakshi 1992MethodsParticipantsRCT, DB, s<strong>in</strong>gle <strong>dose</strong>, 3 parallel groupsMedication adm<strong>in</strong>istered when basel<strong>in</strong>e <strong>pa<strong>in</strong></strong> was of moderate to severe <strong>in</strong>tensityPa<strong>in</strong> assessed at 0, 15, 30 and 60 m<strong>in</strong>s then hourly up to 6 hoursThird molar extractionN = 151M = 70, F = 81Mean age 26 yrsInterventions Diclofenac K 50 mg, n = 51Diclofenac Na (enteric coated) 50 mg, n = 54Placebo, n = 46OutcomesNotesPI: std 4 po<strong>in</strong>t scalePR: 4 po<strong>in</strong>t scale (non std)PGE: 4 po<strong>in</strong>t scale (non std)Ox<strong>for</strong>d Quality Score: R1, DB1, W1Rescue medication permitted after 1 hour. No details about drug used<strong>S<strong>in</strong>gle</strong> <strong>dose</strong> <strong>oral</strong> <strong>diclofenac</strong> <strong>for</strong> <strong>acute</strong> <strong>postoperative</strong> <strong>pa<strong>in</strong></strong> <strong>in</strong> <strong>adults</strong> (Review)Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.25